Is Akero Therapeutics, Inc. (AKRO) a Buy, Sell, or Hold?
NASDAQ : AKRO
Akero Therapeutics, Inc.
$54.65 USD
$0 (0.0%)
- Volume
- 11.61M
- Average Volume
- 2.56M
- Market Capitalization
- $4.5B
- P/E Ratio
- -19.87
- Dividend Yield
- 0.00%
- Price Target
- $54.00
- Year High
- $58.40
- Year Low
- $21.34
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.83
Company Overview
NASDAQ
Andrew Cheng
Biotechnology
Healthcare
AKRO
69
US
USD
Liquidity Metrics
0.00
15.83
15.83
3.69
0.00
Sales & Valuation
-$
0.00
4.68
-24.57
-2.23
Profitability
-$3.75
-$252.06M
0.00%
0.00%
-21.79%
-22.16%
P/E Metrics
-19.87
-88.50
-88.50
Analyst Price Target & Rating
$54.00
$56.00
$38.00
0/5
14 Analysts
1.20%
Financial Health Scores
54.74
2/9
$706.88M
$1.01B
$47.94M
-$288.2M
Key Metrics (TTM)
$4.32B
0.00
-19.71
15.83
-21.79%
-26.28%
-4.97%
-4.07%
0 days
Company Executives
| Name | Title |
|---|---|
| William R. White | Executive Vice President, Chief Financial Officer, Treasurer & Head of Corporate Development |
| Andrew Cheng | President, Chief Executive Officer & Director |
| John J. Schembri | Senior Vice President & Head of Finance |
| Patrick Lamy | Senior Vice President of Commercial Strategy |
| Scott A. Gangloff | Chief Technical Officer |
| Catriona Yale | Executive Vice President & Chief Development Officer |
| Jonathan Young | Co-Founder, Executive Vice President, Chief Operating Officer & Secretary |
| Timothy Rolph | Co-Founder & Chief Scientific Officer |
| Thomas Ross | Senior Vice President & Head of Legal |
Poll Results
No votes yet today — be the first to share your view!
About Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., ... the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Frequently Asked Questions
-
What is the current Akero Therapeutics, Inc. (AKRO) stock price?
-
Akero Therapeutics, Inc.(NASDAQ:AKRO) stock price is $54.65 in the last trading session. During the trading session, AKRO stock reached the peak price of $58.4 while $21.34 was the lowest point it dropped to. The percentage change in AKRO stock occurred in the recent session was 0.0% while the dollar amount for the price change in AKRO stock was $0.
-
AKRO's industry and sector of operation?
-
The NASDAQ listed AKRO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AKRO?
-
William R. White | Executive Vice President, Chief Financial Officer, Treasurer & Head of Corporate Development
Andrew Cheng | President, Chief Executive Officer & Director
John J. Schembri | Senior Vice President & Head of Finance
Patrick Lamy | Senior Vice President of Commercial Strategy
Scott A. Gangloff | Chief Technical Officer -
How many employees does AKRO have?
-
Number of AKRO employees currently stands at 69. AKRO operates from 601 Gateway Boulevard, South San Francisco, CA 94080, US.
-
Link for AKRO official website?
-
Official Website of AKRO is: https://www.akerotx.com
-
How do I contact AKRO?
-
AKRO could be contacted at phone #650 487 6488 and can also be accessed through its website. AKRO operates from 601 Gateway Boulevard, South San Francisco, CA 94080, US.
-
How many shares of AKRO are traded daily?
-
The average number of AKRO shares traded daily for last 3 months was 2.56M.
-
What is the market cap of AKRO currently?
-
The market value of AKRO currently stands at $4.5B with its latest stock price at $54.65